In Silico Prediction of Isoliquiritigenin and Oxyresveratrol Compounds to BCL-2 dan VEGF-2 Receptors by Mutiah, Roihatul et al.
 51
Indonesian Journal of Cancer Chemoprevention, June 2019
ISSN: 2088–0197
e-ISSN: 2355-8989
In Silico Prediction of Isoliquiritigenin and Oxyresveratrol 
Compounds to BCL-2  dan VEGF-2 Receptors
Roihatul Mutiah*, Muhammad Fawwaz Hariz, Yen Yen Ari Indrawijaya, Burhan Ma'arif




 Isoliquiritigenin and oxyresveratrol are compounds that have been reported to 
have anticancer activities. This study aimed to predict cytotoxic activity, toxicity and 
physicochemical properties of the compounds isoliquiritigenin and oxyresveratrol. 
Prediction of physicochemical properties referred to Lipinski rules of five using 
the pkCSM online tool. Prediction of compounds toxicity using Protox II online tool 
while ligand interaction with receptors using Molegro Virtual Docker (MVD). Vascular 
Endothelial Growth Factor Receptor-2 (VEGFR-2) (PDB: 2RL5) and B Cell Lymphoma BCL-
2 (PDB: 4AQ3) were used as target cancer receptor proteins. In silico predictive results 
showed that oxyresveratrol and isoliquiritigenin complied with Lipinski rules of five, 
predictive values of LD50 between 500-2000 mg/kg respectively 1560 mg/kg and 1048 
mg/kg. The docking result was in the form of bound energy described by Rerank Score 
(RS). A compound having a small RS value was predicted to have greater activity. RS of 
oxyresveratrol on 2RL5: -73.0413 and 4AQ3: -87.9985, while isoliquiritigenin on 2RL5: 
-68.0282 and 4AQ3: -78.5041. The cytotoxic activity of oxyresveratrol was also shown 
by hydrogen bonds in active amino acids (2RL5: Cys 919 in 4AQ3: Tyr 67). From docking 
results of both compounds, oxyreveratrol had greater activity than isoliquiritigenin to 
both target cancer receptor proteins and complied Lipinski rules of five and have a low 
toxicity.
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INTRODUCTION
 Cases of cervical cancer in the world are 
estimated to have more than 570,000 with 83% 
caused by Human Papilloma Virus (HPV) and two-
thirds of these cases occur in developing countries 
(Martel, et al., 2017). Chemotherapy and radiother-
apy are used as therapies for cervical cancer (Liu, 
2018). The resistance of chemotherapy drugs in-
cluding cisplatin has become an important problem 
in the treatment of cervical cancer (Wang, et al., 
2015). So that it can be found and developed an-
ti-cancer drugs from natural ingredients (Kinghorn, 
2008). Isoliquiritigenin and oxyresveratrol are 
compounds that have been isolated from Eleuth-
erine palmifolia (L.) Merr, Glycyrrhiza uralensis, 
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Sinofranchetia chinensis, Dalbergia odorifera and 
Glycine max (L.) Merr. Both of these compounds 
have been reported to have anticancer activities in 
vitro (Minggarwati, 2018, Ayeka, et al., 2016; Cao, 
et al., 2004; Pan, et al., 2000; Chan, et al., 1998; 
Kape, et al., 1992). The development of anticancer 
drugs that have specific molecular targets is one of 
the strategies to overcome cancer. The two main 
targets in this study are apoptosis induction cancer 
cell and antiangiogenic. Apoptosis is programmed 
cell death which plays an important role in main-
taining the body's homeostasis. Failure of apopto-
sis is a major factor in cancer cell malignancy. The 
approach to treating cancer through the mechanism 
of apoptosis induction has been known to be able to 
prevent promotion, progression and re-emergence 
of cancer (Rastogi and Sinha, 2009). Implementa-
tion of apoptosis clinical activities produces the ef-
fects of chemotherapy and chemopreventive (Sun, 
et al., 2004). Apoptosis in the mitochondrial path-
way has two pathways, the extrinsic pathway and 
intrinsic pathway. The extrinsic pathway involves 
Fas, while the intrinsic pathway involves cyto-
chrome c (cyt-c) released from mitochondria (Ku-
mar, 2005). The intrinsic pathway is mediated by 
the Bcl-2 family. This apoptotic regulation is carried 
out by antiapoptotic (Bcl-2 and Bcl-xl) and pro-ap-
optotic (Bax and Bak) proteins. These proteins play 
a role in the regulation of apoptosis through reg-
ulation of release cyt-c. The expression of Bcl-2 
or Bcl-xl prevents the release of cyt-c from mito-
chondria. Direct addition of Bax to mitochondrial 
isolates can induce the release of cyt-c (Igney and 
Krammer, 2002). In the cytosol cyt-c will form a 
complex with apaf1 (Apoptotic Protease Factor-1), 
ATP and procaspase-9. This complex is called the 
apoptosome. Cancer growth is also often associated 
with expression of Vascular Endothelial Growth 
Factor Receptor-2 (VEGFR-2) as a proangiogenic 
pathway to increase the angiogenesis stage includ-
ing vascular permeability, endothelial cell survival, 
proliferation, migration or invasion of surrounding 
tissues, and formation capillary blood vessels (Fer-
rara, 2009). The pathway mechanism VEGFR-2 is 
blockade of activation of tyrosine kinase (Hoi, et 
al., 2014). Receptor tyrosine kinases can mediate 
Angiogenesis (Jeltsch, et al., 2013). In this study, 
we performed the prediction of cytotoxic activity, 
toxicity and physicochemical properties of the two 
compounds to VEGFR-2 and BCL-2 receptors. 
METHODS
Software
 Chem Bio Ultra 12.0, pkCSM on line tool, 
Protox II online tool, Molegro Virtual Docker 5.5, 
Molegro Data Modeller 3.0.
Target and Template Selection
 PDB of BCL-2: 4AQ3 and VEGFR-2: 2RL5 
taken from Protein Data Bank (https://www.rcsb.
org). The SMILES code is taken from PubChem 
Compound (https://pubchem.ncbi.nlm.nih.gov/). 
Prediction of Physicochemical Properties 
and Toxicity
 Physicochemical properties and toxicity 
prediction used the SMILES format and  pkCSM 
online tool (Pires, 2015), then categorized into Lip-
inski rules of five. Toxicity predictions used the 
Protox II Online tool anad categorized as toxicity 
classes (Drwal, 2014). 
Molecular Docking Study
 Docking is done using Molegro Virtual 
Docker software 5.5. Identification of ligand bonds 
is carried out by evaluating repeated identification 
and estimating bond energy with a macromolecule 
(CLCbio, 2013). Isoliquiritigenin and oxyresver-
atrol compounds drawn 2D first then transferred into 
a 3D shape using Ultra Chem 12.0. Validation of 
methods done by ligands already present in proteins 
VEGFR-2 (PDB: 2RL5) and BCL-2 (PDB: 4AQ3) 
and performed the docking process. Programs that 
can return poses below RMSD value less than 2 Ǻ 
is considered to have performed successfully (Hev-
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ener, et al., 2009). Furthermore, the existing ligand 
are replaced with isoliquiritigenin and oxyresver-
atrol by conducting alignment and docking sim-
ulations carried out for each of these compounds. 
Protein  2RL5 has a chain protein and 4AQ3 has six 
chains and each of which is filled with ligand. The 
results obtained are the value of root mean square 
deviation (RMSD) and rerank score (RS), which 
is the bond energy required in the ligand-receptor 
interaction process (Siswandono, 2016). Bond  en-
ergy indicated the amount of energy needed to form 
bonds between ligands and receptors. The lower the 
bond energy, the more stable the  bond.  The  more 
stable  the  ligand  bond  with  the receptor, the 
higher the activity (Hardjono, 2012).
RESULTS
Prediction of Physicochemical Properties 
and Toxicity
 The results of absorption and permeability 
prediction to oxyresveratrol and isoliquiritigenin 
compounds using Lipinski rules of five showed 
that  the  four  physicochemical  properties  were 
Log p<5, Molecular Weight <500, H bond donor <5 
and H bond acceptor <10. Based on these results, 
two compound  meet  the  Lipinski  rules  of  five 
requirements so it can be predicted that the com-
pounds  will  be  easily absorbed  and  have  high 
permeability (Lipinski, et al., 1997). Physicochemi-
cal  Properties  prediction  is  presented  in  Table  1. 
Table 1. Prediction of physicochemical properties.
Description: A: Molecular Weight, B: Partition Coefficient, C: Number of Rotatable Bonds (Torsion), D: Hydrogen Bond 
Donors (HBD), E: Hydrogen Bond Acceptors (HBA), F: Polar Surface Activity, G: AMES Mutagenic Test, H: Toxic to the 
liver, I: Skin sensitization, J: LD50 (mg/kg), K: Toxicity classes. class IV= harmfull is swallow (300-2000) Class IV = 
maybe harmful swallow (2000-5000). *pkCSM Online Tool **Protox II Online Tool.
A* B* C* D* E* F* G* H* I* J** K**
Isoliquiritigenin
256.257 2.6995 3 3 4 109.438 No No No 1048 IV Yes
Oxyresveratrol
244.246 2.6794 2 4 4 103.706 Yes No No 1560 IV Yes
2,3-dihydro-1, 4-benzoxazine inhibitor
491.931 6.1286 5 1 6 206.494 No Yes No 5000 V No
Phenylacylsulfonamide inhibitor
866.222 7.9515 12 1 7 328.24 No Yes No 370 IV No
Compound
Physicochemical Properties Toxicity    Lipinski Rules 
       of Five
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Figure 1. The two-dimensional interactions are shown between the test compounds against the VEGFR-2 (A) and 
BCL-2 Chain E (B) receptors with their respective native ligands. 
Table 2. Validation receptor and RMSD values.
 The results of toxicity prediction show 
that the  test  compounds  of  isoliquiritigenin 
and oxyresveratrol  and  the comparative com-
pound  phenylacylsulfonamide inhibitor belong 
to category four toxicity, namely slightly toxic 
(lethal dose (LD)50 300-2000 mg/kg body weight 
(BW)). Comparative compounds (2,3-dihydro-1, 
4-benzoxazine inhibitors) are included in cate-
gory  five  toxicity,  namely  practically  nontoxic 
(LD50 2000-5000 mg/kg BW). The toxicity predic-
tion  results of isolquiritigenin, oxyresveratrol, and 
comparative compounds are presented in Table 1. 
Based on Table 1, isoliquiritigenin compound was 
not mutagenic in the AMES mutagenic test, no 
hepatotoxic in  hepatotoxicity tests and no cause 
skin irritation in skin sensitization tests. Oxyresver-
atrol compound showed that is mutagenic in AMES 
mutagenic test, but did not cause hepatotoxicity and 
skin sensitization. Both comparative compounds 
could be predicted to be hepatotoxic but no muta-
genic and no toxic to the skin.
A B
Receptor VEGFR-2 BCL-2 Chain A BCL-2 Chain B BCL-2 Chain C BCL-2 Chain D BCL-2 Chain E BCL-2 ChainF
RMSD values 1.18875 4.43089 11.3424 2.76257 10.8581 0.780526 3.42542
Validation of Receptor
 The RMSD values between the generated 
poses and  the bound native ligand of crystal struc-
ture VEGFR-2 (2RL5) and BCL-2 (4AQ3) are 
shown in Table 2. Based on Table 2 Validation re-
sults are shown with the RMSD value. Valid RMSD 
values  lass then 2 Ǻ (Hevener. et al., 2009). It was 
found that poses receptors with native ligand has 
valid. RSMD in VEGFR-2 show value 1.18875 Ǻ 
and RMSD in BCL-2 chain E is lower than all chain 
with value RMSD 0.780526 Ǻ. 
Docking Molecular and Interaction
  The result of molecular docking and in-
teractions get the best position between ligands 
and receptors. The best position that has been 
done was where the ligand attaches to the recep-
tor. The results of the best position of the test li-
gands and native ligands on the VEGFR-2 and 
BCL-2 Chain E receptors are shown in Figure 1.
VEGFR-2 showed hydrogen bond and steric in-
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Figure 2. Two dimensions form of hydrogen and steric bonds between (A) 2,3-dihydro-1, 4-benzoxazine inhib-
itors (B) Isoliquiritigenin and (C) Oxyresveratrol with VEGFR-2 receptors (2RL5); blue lines as hydrogen 
bonds and red lines as steric bonds.
teraction that occurs between amino acid recep-
tors and ligands. The ligand isoliquiritigenin
had hydrogen bonds with amino acids Thr 916, Cys 
919, Lys 868, Val 914 and steric bonds Cys 919, Val 
848, Val 914. The ligand oxyresveratrol had hydro-
gen bonds with amino acids Glu 917, Cys 919, Lys 
868, Val 914 and steric bond Ala 866. The native lig-
and 2,3-dihydro-1,4-benzoxazine inhibitors had hy-
drogen bonds with amino acids Cys 919, Asp 1046, 
and steric bonds Asp 1046. The bond results with 
the amino acid VEGFR-2 are presented in Figure 2.
BCL-2 showed hydrogen bond and steric interac-
tion that occurs between amino acid receptors and 
ligands. The ligand of isoliquiritigenin had hydro-
gen bonds with amino acids Arg 66 (E), Asp 62 (A), 
Arg 105 (E), Tyr 67 (E) and steric bonds Gly 104 
(E),Arg 66 (E). The ligands of oxyresveratrol had 
hydrogen bonds with amino acids Leu 160 (A), Ala 
59 (E), Gln 58 (A), Tyr 67 (E). The native ligands 
had hydrogen bonds with amino acids Gly 162 (A), 
Gln 58 (A), Tyr 67 (E) and steric interaction Phe 
63 (E), Leu 96 (E), Glu 95 (E). The bond results 
between the amino acid and  BCL-2 are shown in 
Figure 3. 
Figure 3. Two dimensions from of hydrogen bonds between (A) Phenyl-acyl-sulfonamide inhibitor (B) Isoliquir-
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 The docking results between isoliquir-
itigenin and oxyresveratrol compounds to both 
VEGFR-2 receptor (2RL5) and native ligand 
2,3-dihydro-1,4-benzoxazine inhibitors, then to 
both BCL-2 Chain E receptors (4AQ3-E) and na-
tive ligands phenylacylsulfonamide inhibitors had 
a  ranging of RS from -68.0282 to -123,998. The 
two test ligands had a RS greater than the native 
ligand of each receptor. The docking results show 
that each receptor has the same amino acid at the 
VEGFR-2 receptor, Cys 919 and BCL-2, Tyr 
67. The docking results are presented in Table 3.
DISCUSSION
 This study aims to predict the physico-
chemical properties, toxicity and cytotoxic activ-
ity through in silico test of isoliquiritigenin and 
oxyresveratrol compounds. In both compounds test, 
isoliquiritigenin and oxyresveratrol fulfill the Lip-
inski rules of five with the meaning that it can be 
absorbed well and had good permeability while the 
comparative compounds did not meet the Lipinski 
rules of five because it have a molecular weight of 
≥ 500 and HBA ≥ 10. All compounds have LD50 
value between 500-2000 mg/kg BW with V and IV 
grade toxicity which showed relatively low toxic-
ity. The higher the LD50 value, the lower the toxic-
ity (Supandi, et al., 2018). The compound will be 
difficult to absorb and its permeability is low if it 
has: its molecular weight is ≥ 500, the log value of 
the partition coefficient is octanol/water (log P) ≥ 
+5; donor H-bond (HBD), expressed by the num-
ber of OH and NH groups, ≥ 5; and H-receptor 
bonds (HBA) expressed by the number of atoms O 
and N, ≥ 10 (Lipinski, et al., 1997). Through ful-
filling the Lipinski rules of five criterias, showed 
that isoliquiritigenin and oxyresveratrol com-
pounds had good absorption and permeability.
 Native ligands of 2RL5 and 4AQ3 coor-
dinates were used for all docking experiments. In 
ordered to validate the scoring function, before re-
docking molecules for selecting prospective hits, we 
preparation into 2RL5 and 4AQ3 protein structure 
in MVD. there is one chain of VEGFR-2 protein in 
2RL5 were each charged with its ligand and There 
are 6 chains of BCL-2 protein in 4AQ3 were each 
charged with its ligand. Subsequently, we com-
pared the conformation and position with the bound 
ligand conformation measured regarding the root-
mean square deviation (RMSD). Isoliquiritigenin 
and oxyresveratrol structures are docked to the re-
ceptor at the same place and coordinates previously.
 In Table 3, the RS of VEGFR-2 receptor 
with an oxyresveratrol ligand had a smaller than li-
gand isoliquiritigenin, but the two test ligands are 
still higher when compared to native ligands 2,3-di-
hydro-1,4-benzoxazine inhibitors. This might be 
caused the hydrogen bond in the native ligand was 
more on the active side. The RS of BCL-2 recep-
tor and oxyresveratrol ligand had a smaller value 
than the isoliquiritigenin ligand but the two ligands 
are not smaller than the native ligand (phenylacyl-
sulfonamide inhibitor). A low RS can be attributed 
to the interaction of active amino acid bonds and 
also a less strong bond distance. RS or bond en-
ergy was the total calculation of all existing bonds. 
Bond energy stated the amount of energy needed 
to carry out interactions between ligands and re-
ceptors (Nugroho, 2014). The smaller RS indi-
cates more stable bonds and results in increased 
activity (Thomsen, et al., 2006; Hincliffe, 2008; 
Kusumaningrum, et al., 2014; Hardjono, 2012). 
 The similarity of Cys 919 amino acid resi-
due involved in the binding process of the VEGFR-2 
receptor will cause the compound to inhibit the re-
ceptor activity by competitive inhibitors (Figure 2). 
This mechanism occured through the blockade of 
tyrosine kinase activation from VEGFR-2 (Hoi, et 
al., 2014). It was reported in previous studies that 
the interaction of ligands with amino acids Cys 
919 can be observed as the active side (La, et al., 
2008). Amino acid Lys 868 can be responsible as 
the active side and increase receptor bond energy 
(Ebadi, et al., 2012). The role of Glutamic Acid 
(Glu) in hydrogen bonds has been explained to have 
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Table 3. Rerank score, hydrogen bond and steric interaction.
Receptors Compounds Hidrogen Bound  and Distance (Ǻ)
Steric Interaction and 
Distance (Ǻ) Rerank Score
Cys 919 (2.87)
Asp 1046 (2.70)
Thr 916 (3.16) Cys 919 (3.04)







Gly 162 (A) (3.11) Phe 63(E) (3.15) 
Gln 58 (A) (2.81) Leu 96(E) (3.07)
Tyr 67 (E) (3.10) (3.19) Glu 95(E) (3.14)
Arg 66 (E) (3.04) Gly 104(E) (2.98)
Asp 62 (A) (2.74) Arg 66 (E) (3.06)
Arg 105 (E) (2.63)
Tyr 67 (E) (3.05)
Leu 160 (A) (3.06)
Ala 59 (E) (2.58)
Gln 58 (A) (3.09)









Asp 1046 (3.15) -123.998
Isoliquiritigenin -68.0282
Val 914 (2.99)
Oxyresveratrol Ala 866 (3.07) -73.0413
a role in inhibiting tumor development by suppress-
ing the process of angiogenesis and permeability 
through the VEGFR-2 pathway (Baek, et al., 2017). 
  The similarity of tyrosine (Tyr) 67 (E) 
amino acid residue in both ligand and native ligand 
inhibitors test found that these amino acids were 
the active side of the BCL-2 receptor (4AQ3) (Fig-
ure 3). The Tyr 67 (E) amino acid residue is found 
in the BH-3 domain of BCL-2 (Kennedy, et al., 
2015). This bond resulted in the activation of BH-3 
as pro-Apoptosis. Pro-apoptosis will compete with 
anti-apoptosis, so when more apoptosis will medi-
ate the release of cytochrome-C from mitochondria. 
After cytochrome-C exits from the mitochondria 
cytochrome-C will be bound by Apaf-1 (Apoptosis 
Activating Factor), then it will be bound and form a 
CARD domain (Caspase Recruitment Domain) and 
form Apoptosome. Apoptosome will activate cas-
pase 9 then activate caspase 3. Caspase 3 is a medi-
ator of cell death (apoptosis) (Chipuk, et al., 2010). 
CONCLUSION
 Isoliquiritigenin and oxyresveratrol com-
pounds complied Lipinski rules of five and have 
a low toxicity. Oxyresveratrol compound had 
greater activity than isoliquiritigenin caused had 
lower rerank score. The activity of oxyresver-
atrol was also shown by hydrogen bonds in active 
amino acids (2RL5: Cys 919 in 4AQ3: Tyr 67). 
58
Mutiah, et al., 2019
Indones. J. Cancer Chemoprevent., 10(2), 51-59
REFERENCES
Ayeka, P.A., Bian, Y., Mwitari, P.G., Chu, X., Zhang, 
Y., Uzayisenga, R. and Otachi, E.O., 2016, Im-
munomodulatory and anticancer potential of 
Gan cao (Glycyrrhiza uralensis Fisch.) polysac-
charides by CT-26 colon carcinoma cell growth 
inhibition and cytokine IL-7 upregulation in 
vitro, BMC complementary and alternative 
medicine, 16, 206. 
Baek, Y.Y., Lee, D.K., Kim, J., Kim, J.H., Park, W., 
Kim, T., Han, S., Jeoung, D., You, J.C., Lee, H., 
Won, M.H., Ha, K.S., Kwon, Y.G. and Kim, Y.M., 
2017, Arg-Leu-Tyr-Glu Tetrapeptide Inhibits Tu-
mor Progression By Suppressing Angiogenesis 
and Vascular Permeability Via Vegf Receptor-2 
Antagonism, Oncotarget, 8(7), 11763-11777.
Cao, Y., Wang, Y., Ji, C. and Ye, J., 2004, Determi-
nation of Liquiritigenin and Isoliquiritigenin In 
Glycyrrhiza Uralensis and Its Medicinal Prepara-
tions By Capillary Electrophoresis With Electro-
chemical Detection, Journal of Chromatogr A, 
1042, 203–209. 
Chan, S.C., Chang, Y.S., Wang, J.P., Chen, S.C. and 
Kuo, SC., 1998, Three new flavonoids and an-
tiallergic, anti-inflammatory constituents from 
the heartwood of Dalbergia odorifera, Planta 
Medica, 64, 153–158.
Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, 
M.J. and Green, D.R., 2010, The BCL-2 family 
reunion, Molecular cell, 37, 299–310.
CLCbio, 2013, Molegro Virtual Docker User Manual, 
MVD 2013.6.0 for Windows, Linux, and Mac OS 
X, Molegro A CLC bio company.
Drwal, M.N., Banerjee, P., Dunkel, M., Wettig, M. R. 
and Preissner, R., 2014, ProTox: a web server for 
the insilico prediction of  rodent oral toxicity, 
Nucleic Acids Research, 42(W1), W53–W58. 
Ebadi, A., Razzaghi-Aslc,N., Shahabipour, S. and Miri, 
R., 2014, Ab-Initio And Conformational Analysis 
of A Potent Vegfr-2 Inhibitor: A Case Study on 
Motesanib, Ira nian Journal of Pharmaceutical 
Research, 13(2), 405-415.
Ferrara, N., 2009, VEGF-A: a critical regulator of 
blood vessel growth, Eur. Cytokine Netw., 
20(4), 158-163.
Hardjono, S., 2012, Modifikasi struktur 1-(benzoiloksi) 
urea dan hubungan kuantitatif struktur-aktivitas 
sitotoksiknya [modification of 1-(benzoyloxy)
urea structure and the quantitative relationship 
between its structure and cytotoxic activities], 
Dissertation. [Surabaya]: Airlangga University.
Hinchliffe, A., 2008, Molecular Modeling for Begin-
ners. 2nd ed., Chichester: John Wiley and Sons 
Ltd.
Hoi, P.M., Li, S., Vong, C.T., Tseng, H.H.L., Kwan, 
Y.W. and Lee, S.M-Y., 2014, Recent Advances in 
Structure-Based Drug Design and Virtual Screen-
ing of Vegfr Tyrosine Kinase Inhibitors, Methods, 
71, 85-91.
Igney F.H. and Krammer P.H., 2002, Review: death 
and antideath: tumor resistance to apoptosis, 
Nat Rev Cancer, 2(4), 277-88.
Jeltsch, M., Leppänen, V.M., Saharinen, P. and Ali-
talo, K., 2013, Receptor tyrosine kinase-medi-
ated angiogenesis, Cold Spring Harb Perspect 
Biol., 15(9), a009183.
Kape, R., Parniske, M., Brandt, S. and Werner, D., 
1992, Isoliquiritigenin, A Strong Nod Gene- and 
Glyceollin Resistance-inducing Flavonoid from 
Soybean Root Exudate, Appl Environ Microbiol., 
58, 1705–1710. 
Kartasasmita, R.E., Herowati, R. and Gusdinar, T., 
2010, Docking Study of Quercetin Derivatives on 
Inducible Nitric Oxide Synthase and Prediction 
of Their Absorption and Distribution Properties, 
Journal of Applied Sciences, 10(23), 3098-3104.
Kennedy, R.K., Veena, V., Ravindra, P., Naik, Lakshmi, 
P., Krishna, R., Sudharani, S. and Sakthivel, N., 
2015, Phenazine-1-carboxamide (PCN) from 
Pseudomonas sp. strain PUP6 selectively in-
duced apoptosis in lung (A549) and breast (MDA 
MB-231) cancer cells by inhibition of antiapop-
totic Bcl-2 family proteins, International Jour-
nal on Programmed Cell Death, 20(6), 858-868.
Kinghorn, A.D., Drug discovery from natural products. 
In: Lemke, TL.; Williams, DA., Foye’s, 2008, 
ACKNOWLEDGEMENTS
 Thank you to Prof. Dr. Siswandono, Apt., 
M.S. for giving access to the application of Mole-
gro Virtual Docker 5.5.
 59
Indonesian Journal of Cancer Chemoprevention, June 2019
ISSN: 2088–0197
e-ISSN: 2355-8989
Principles of Medicinal Chemistry. 6th Edition. 
Philadelphia, PA, USA: Wolters Kluwer/Williams 
& Wilkins.
Kumar, V., Cotran, R.S. and Robins, S., 2005, Basic 
Pathology 7th Ed. Penerbit Buku Kedokteran 
EGC, Jakarta.
Kusumaningrum, S., Budianto, E., Kosela, S., Sumary-
ono, W. and Juniarti, F., 2014, The molecular 
docking of 1,4-naphthoquinone derivatives as 
inhibitors of Polo-like kinase 1 using Molegro 
Virtual Docker, Journal of Applied Pharmaceu-
tical Science, 4(11), 047-053
La, D.S., Belzile, J., Bready, JV., Coxon, A., DeMelfi, 
T., Doerr, N., Estrada, J., Flynn, J.C., Flynn, 
S.R., Graceffa, R.F., Harriman, S.P., Larrow, 
J.F., Long, A.M., Martin, M.W., Morrison, M.J., 
Patel, V.F., Roveto, P.M., Wang, L., Weiss, M.M., 
Whittington, D.A., Teffera, Y., Zhao, Z., Polv-
erino, A.J. and Harmange, J.C., 2008, Novel 
2,3-dihydro-1,4-benzoxazines as potent and 
orally bioavailable inhibitors of tumor-driven 
angiogenesis, Journal of Medicinal Chemistry, 
51(6), 1695-1705.
Lipinski, C.A., Lombardo, F., Dominy, B.W. and 
Feeney, F.J., 1997, Experimental and compu-
tational approaches to estimate solubility and 
permeability in drug discovery and development 
settings, Advanced Drug Delivery Reviews, 23, 
3-25.
Liu, Y.M., Ni, L.Q.,Wang, S.S,, Lv, Q,L,, Chen, W.J. 
and Ying, S,P., 2018, Outcome and prognostic 
factors in cervical cancer patients treated with 
surgery and concurrent chemoradiotherapy: a 
retrospective study, World Journal of Surgical 
Oncology, 16(18), 1-7.
Martel, C.D., Plummer, M., Vignat, J. and Franceschi, 
S., 2017, Worldwide burden of cancer attribut-
able to HPV by site, country and HPV type, In-
ternational Journal of Cancer, 141, 664–670.
Minggarwati, 2017, Uji Aktivitas Antikanker dan Iden-
tifikasi Senyawa Aktif dari Fraksi Umbi Bawang 
Sabrang (Eluetherine palmifolia (L.) Merr.) 
Terhadap, Sel Kanker Hela. [SKRIPSI]. Malang. 
Universitas Islam Negeri Maulana Malik Ibrahim 
Malang.
Pan, X., Kong, L., Zhang, Y., Cheng, C. and Tan, R., 
2000, In Vitro Inhibition of Rat Monoamine Ox-
idase by Liquiritigenin and Isoliquiritigenin Iso-
lated from Sinofranchetia Chinensis, Acta Phar-
macol Sin., 21, 949–953.
Pires, D.E.V., Blundell, T.L. and Ascher, D.B., 2015, 
pkCSM: Predicting Small-Molecule Pharmacoki-
netic and Toxicity Properties Using Graph-Based 
Signatures, Journal of Medical Chemistry, 58, 
4066-4072.
Rastogi, R.P. and Sinha, R.P., 2009, Apoptosis: molec-
ular mechanisms and pathogenicity, EXCLI Jour-
nal, 8, 155–181.
Siswandono, editor, 2016, Kimia medisinal I [Medic-
inal chemistry I], 2nd edition, Surabaya, Air-
langga University Press.
Sun, S., Hail Jr., N., and Lotan, R., 2004, Apoptosis 
as a novel target for cancer chemoprevention, 
Journal of the National Cancer Institute, 96(9), 
662-272.
Supandi., Yeni.  and   Merdekawati F.,  2018,  In   Sil-
ico  Study  of  Pyrazolylaminoquinazoline  Tox-
icity   by Lazar, Protox, and Admet Predictor, 
Journal of Applied    Pharmaceutical   Science, 
8(09), 119-129.
Thomsen, R.  and  Christensen, M.H., 2006, Mol 
Dock: A  New Technique  for  High-Accuracy  Mo-
lecular Docking, Journal  of Medical  Chemistry, 
49(11), 3315-3321.
